Chlorthalidone for Poorly Controlled Hypertension in Chronic Kidney Disease: An Interventional Pilot Study

14 subjects with moderate to advanced chronic kidney disease (estimated GFR 20-45 ml/min/1.73 m2) and poorly controlled hypertension confirmed by 24-hour ambulatory BP monitoring. Average age 67.5 years, median 4 antihypertensive drugs used.

Chlorthalidone 25 mg/day added to existing medications, with the dose doubled every 4 weeks if BP remained elevated, for a 12-week treatment phase.

Change in 24-hour ambulatory blood pressure at 12 weekssurrogate